The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment

Qvigstad, C., Tait, R. C. , Rauchensteiner, S., Berntorp, E., de Moerloose, P., Schutgens, R. E. and Holme, P. A. (2018) The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine, 97(39), e12551. (doi: 10.1097/MD.0000000000012551) (PMID:30278553) (PMCID:PMC6181599)

[img] Text
244195.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

228kB

Abstract

Chronic liver disease (CLD) is frequently seen in the hemophilia population. The ADVANCE Working Group conducted a cross-sectional study in which people with hemophilia (PWH) aged ≥40 years were included. This study aimed to assess the associations between CLD and its risk factors using data from the H3 study, and to suggest implications for optimal care. Data from 13 European countries were collected at a single time-point (2011–2013). Univariate and multivariate logistic regression (MLR) analyses were performed. A total of 532 PWH were included with either hemophilia A (n = 467) or hemophilia B (n = 65). A total of 127 (24%) were diagnosed with CLD. Hepatitis C virus (HCV), human immunodeficiency virus (HIV), total cholesterol, and severe hemophilia were significant risk factors in univariate logistic regressions. In MLR, HCV Ab+/PCR+ (OR = 17.6, P < .001), diabetes (OR = 3.0, P = .02), and HIV (OR = 1.9, P = .049) were positively associated with CLD. Total cholesterol (OR = 0.6, P = .002) was negatively associated with CLD. We found no evidence of interaction effects among the explanatory variables. No significant associations with age and type of or severity of hemophilia were observed in MLR. The main risk factors for CLD in this European cohort also apply to the general population, but the prevalence of HCV and HIV is considerably larger in this cohort. With new and improved treatment options, intensified eradication therapy for HCV seems justified to prevent CLD. Similarly, intensified monitoring and treatment of diabetes seem warranted.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Tait, Dr Robert
Authors: Qvigstad, C., Tait, R. C., Rauchensteiner, S., Berntorp, E., de Moerloose, P., Schutgens, R. E., and Holme, P. A.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Medicine
Publisher:Lippincott, Williams & Wilkins
ISSN:0025-7974
ISSN (Online):1536-5964
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Medicine 97(39): e12551
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record